BG Medicine Up 9% As Its Galectin-3 Test Aids La Jolla Pharmaceutical Phase 2 Kidney Disease Clinical Trial


BG Medicine (BGMD) is up 9% after it says it welcomes the positive results from La Jolla Pharmaceutical’s (LJPC) Phase 2 Clinical Trial targeting Galectin-3 in Chronic Kidney Disease announced Monday.

The trial met specifically targeted endpoints at the effective therapeutic dosage as measured using BGMD’s BGM Galectin-3 Test. These positive results include meeting the primary efficacy endpoint of improved kidney function and key secondary endpoints including reducing galectin-3 circulating levels.

The diagnostic healthcare company is recently at $1.37 per share, up 8.8% on 4.8 million shares, more than twice average daily volume. BGMD shares trade near the middle of a 52-week price range of $0.55 – $2.24 per share.

After jumping more than 64% in Tuesday’s trading following Monday’s clinical trial news, LJPC is recently down 10.5% at $16.08 per share in late Wednesday trading.

Suggested Reading: Most Popular TV Episodes